Genetic testing can confirm a muscular dystrophy (MD) diagnosis when symptoms and other tests already suggest MD. It also identifies specific gene mutations that can guide targeted treatment. Genetic ...
DMD is the result of mutations in the dystrophin gene located on the X chromosome. These mutations lead to the absence or dysfunction of the dystrophin protein, which is essential for muscle stability ...
On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...
Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function. Ongoing research will determine if these advances can deliver ...
As individuals age, maintaining muscular health becomes increasingly crucial, where the loss of muscle mass and strength is linked to a higher risk of falls and reduced physical activity. Now, ...
Spinal muscular atrophy (SMA) type 1 is the most common and most severe form of SMA. Symptoms typically begin in the first 6 months of life. Life expectancy is less than 2 years without treatment, but ...
Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...
This story is from Manual, GQ’s flagship newsletter offering useful advice on style, health, and more, four days a week. Sign up here to get it in your inbox. Despite what many workout equipment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results